Benzinga | Nov 9, 2020 08:19AM EST

Morgan Stanley Maintains Overweight on Epizyme, Lowers Price Target to $27

Morgan Stanley maintains Epizyme (NASDAQ:EPZM) with a Overweight and lowers the price target from $29 to $27.